NCI

NCI’s RPG pool, cancer centers, training awards, SPOREs, and intramural research likely to face cuts in FY24

Center directors are concerned about NCI’s proposal to create a tier of centers with lower eligibility criteria

By Alexandria Carolan and Paul Goldberg

Amid the gridlock that has seized Washington, NCI faces a grim and disturbing FY2024, the institute’s Principal Deputy Director Douglas R. Lowy said at the annual meeting of the Association of American Cancer Institutes.

NCI’s RPG pool, cancer centers, training awards, SPOREs, and intramural research likely to face cuts in FY24

Robert Winn introduces “Inclusive Excellence” as his AACI presidential initiative
“If we’re going to be inclusive, then we need to be inclusive.”

Cancer centers must focus on measurable endpoints in building a diverse workforce, improving health equity

Carpten, Diaz, Elenitoba-Johnson, Leach, Merad, Mukherjee, Newman, Vonderheide, and Wolchok are among NAM 100 new members

In Brief

Monica Bertagnolli’s NIH confirmation hearing scheduled

Katalin Karikó, Drew Weissman awarded 2023 Nobel Prize in Physiology or Medicine for mRNA vaccine research

Moungi G. Bawendi, Louis E. Brus, Alexei I. Ekimov awarded 2023 Nobel Prize in Chemistry for quantum dots

Andrew Mesecar named director of Purdue Institute for Cancer Research

Bradley Monk named medical director of late-phase clinical research at Florida Cancer Specialists

Lawrence Fong named scientific director of Immunotherapy Integrated Research Center at Fred Hutch

Julie Beitz named principal drug regulatory expert at Hyman, Phelps & McNamara

$10.9M NIH grant to establish UH Pacific Center for Genome Research

Walker Foundation pledges $1M to UAMS Rockefeller Cancer Institute to support radiation oncology center

Clinical Roundup

SITC-IBCG publishes bladder cancer clinical trial design recommendations

Phase III trial for Keytruda in lung cancer reaches dual primary endpoint of OS

Phase II study of BXCL701 + Keytruda in small cell neuroendocrine prostate cancer shows positive OS results

Hopkins phase II study suggests liquid biopsy could be early marker of immunotherapy response

Rural hospital system demonstrates clinical benefits of universal hereditary cancer testing in breast cancer

USC researchers develop blood test with the potential to detect early-stage ovarian cancer

City of Hope and TGen research reveals potential cause of aggressive leukemia

New antibody shows strong potential against pancreatic cancer

NYU Perlmutter research suggests drug combination could starve pancreatic cancer

Telomere-targeting agent demonstrates potent anticancer activity in aggressive pediatric brain cancer in preclinical study

Drugs & Targets

FDA approves encorafenib with binimetinib for metastatic NSCLC with a BRAF V600E mutation

Shasqi, Johnson & Johnson expand existing research collaboration

Delfi Diagnostics commercializes blood test for lung cancer screening

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login